COMMUNIQUÉS West-GlobeNewswire

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection
12/05/2026
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) ( [...]
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
12/05/2026
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026
12/05/2026
RTX001 is an engineered Regenerative Macrophage Therapy for end-stage liver disease (ESLD) with anti-inflammatory and anti-fibrotic properties These new preclinical data demonstrate RTX001’s pharmacology, safety, [...]
Four Winners Selected in PerfectServe’s 2026 Nurses of Note Awards Program
12/05/2026
Winners are nurse leaders whose work focuses on mentorship for new nurses, neonatal care and education, and better perioperative care team communication MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- PerfectServe®, a leading [...]
Fortis Life Sciences Awards 2026 AbNano® VHH Discovery Grant to Deliver Biosciences for Targeted Drug Delivery Research
12/05/2026
Grant program expands access to advanced single-domain antibody technologies to support the research and development of next-generation therapies BOSTON and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Fortis Life Sciences [...]
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
12/05/2026
Data will reflect the functional characterization of EVX-04 Poster presentation on June 13, 2026 COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing [...]
BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026
12/05/2026
Treatment with BH-30236, a novel CLK inhibitor, was generally well tolerated as monotherapy and in combination with venetoclax Preliminary anti-leukemic activity observed, including patients that were previously treated [...]
Ontra Launches AI-Powered DDQ Solution to Accelerate Investor Diligence for Private Markets Firms
12/05/2026
Co-developed with leading private markets firms, Ontra’s solution delivers the speed, accuracy, and consistency investor diligence demands SAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) -- Ontra , the leader in AI-powered [...]
PrognomiQ Announces Breakthrough Results for the Early Detection of Lung Cancer in Ongoing Real-World Study for Its Novel Blood Test
12/05/2026
ProVue Lung blood test detects lung cancers with 89% overall sensitivity and 83% sensitivity at stage I, the earliest and most treatable stage SAN MATEO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- PrognomiQ , a healthcare [...]
Mental Health Awareness Month: TPN.health Solves the Access Crisis Costing Self-Insured Stakeholders, Health Plans and Members the Care They Deserve
12/05/2026
NEW ORLEANS, May 12, 2026 (GLOBE NEWSWIRE) -- TPN.health , the operating system for behavioral health, is redefining what access to mental health care means for self-funded employers, health plans and the millions of [...]
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
12/05/2026
Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs’ AI-Enabled Multi-Cancer Early Detection Platform [...]
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
12/05/2026
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability with revumenib [...]
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT [...]
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets
12/05/2026
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications TAMPA, Fla. and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Akari [...]
Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases
12/05/2026
- Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a single AAV vector - Two poster presentations describe methods that support accelerated [...]
Felix Health to Lower Semaglutide Pricing by Up to 65% as Lower-Cost Options Enter Canada
12/05/2026
Canada’s largest virtual weight loss clinic says cost is causing patients to discontinue treatment: Nearly 1 in 4 Felix weight management patients who discontinued their program in the past year cited cost as the #1 [...]
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
12/05/2026
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appointed interim CEO Dr [...]
Immatics Announces First Quarter 2026 Financial Results and Business Update
12/05/2026
SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027 Multiple key clinical data sets [...]
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team [...]

Pages